Navigation Links
CapitalSource Closes First Step of Long-Term Care Facility Sale to Omega Healthcare Investors
Date:12/22/2009

CHEVY CHASE, Md., Dec. 22 /PRNewswire-FirstCall/ -- CapitalSource Inc. (NYSE: CSE) today announced that it has completed the sale of 40 long-term care facilities to Omega Health Care Investors Inc. (NYSE: OHI), as per the terms of the previously announced Securities Purchase Agreement between the parties.

In this closing, CapitalSource received net proceeds from Omega of $234.8 million, consisting of $184.2 million in cash; and 2,714,959 shares of Omega common stock (valued at $50.6 million under the Purchase Agreement). Additionally, Omega assumed $59.4 million of debt associated with the 40 properties purchased. Included in the purchase price was $25 million for an option which can be exercised by Omega to acquire 63 additional long-term care facilities at any time through December 31, 2011 (step three of the Purchase Agreement). CapitalSource expects step two of the transaction for an additional 40 long-term care facilities to close on or about April 1, 2010.

As previously disclosed, CapitalSource expects to use the proceeds from the Omega sale to add to parent company liquidity and reduce the committed capacity of the Company's syndicated bank facility from the current level of $525 million. The Omega stock received by CapitalSource is required to be registered by Omega in the first quarter of 2010.

About CapitalSource

CapitalSource Inc. (NYSE: CSE) is a commercial lender that provides financial products to middle market businesses and offers depository products and services in southern and central California through its wholly owned subsidiary CapitalSource Bank. As of September 30, 2009, CapitalSource had total commercial assets of $10.4 billion and $4.4 billion in deposits. The Company is headquartered in Chevy Chase, MD. Visit www.capitalsource.com for more information.

Forward Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections and including statements about the sale to Omega Care Investors Inc. of assets in our healthcare net lease portfolio, including the purchase option, expected timing of closing of the next step of the transaction, our intended use of proceeds, requirements under our senior secured notes, and the registration of the stock we have received in the transaction, all of which are subject to numerous conditions, requirements, adjustments, options, assumptions, risks, and uncertainties, including the counterparty's discretion regarding whether to exercise its purchase option. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "intend," "believe," "expect," "estimate," "plan," "goal," "will," "outlook," "continue," "look forward," "should," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements (including statements regarding future financial and operating results and future transactions and closings and their results) involve risks, uncertainties and contingencies, many of which are beyond our control which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Actual results could differ materially from those contained or implied by such statements for a variety of factors, including without limitation: the proposed transactions may not be completed on the proposed terms and schedule or at all; we may not generate the expected proceeds; the ability of the parties to satisfy the conditions to the completion of the remaining transactions contemplated by the purchase agreement; potential adjustments to the form and amount of consideration payable in connection with the remaining transactions pursuant to the purchase agreement; potential unforeseen costs associated with the transactions; the stock we received in the transaction may not be registered in the required time period or at all; changes in economic or market conditions; continued or worsening recession in the overall economy or disruptions in credit and other markets; movements in interest rates and lending spreads; continued or worsening credit losses, charge-offs, reserves and delinquencies; our ability to successfully and cost effectively operate our business; competitive and other market pressures on product pricing and services; success and timing of our business strategies; the nature, extent, and timing of governmental actions and reforms; changes in tax laws or regulations affecting our business; and other factors described in CapitalSource's 2008 Annual Report on Form 10-K and documents subsequently filed by CapitalSource with the Securities and Exchange Commission. All forward-looking statements included in this news release are based on information available at the time of the release. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

SOURCE CapitalSource Inc.


'/>"/>
SOURCE CapitalSource Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical
2. Registration Closes Soon for FDAs Second Annual Science Writers Symposium
3. Augmenix, Inc. Closes $6.1 Million Financing
4. Beckman Coulter Announces Third Quarter 2009 Earnings to be Released on Thursday, October 29, 2009, After Market Closes
5. Archi-Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull-Through Reporting Capabilities
6. Greenway Medical Technologies Closes 11th Consecutive Fiscal Year of Positive Growth
7. AdvanDx Closes $8 Million Financing Round and Elects New Board Member
8. HeartWare International, Inc. Closes US$60 Million Financing
9. Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days
10. Croff Enterprises, Inc. Closes Merger and Will Change Name to Americas Minority Health Network, Inc.
11. Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Cranbury, NJ (PRWEB) , ... February 23, 2017 ... ... Cure®, the pre-eminent publication and community for those in the fight against cancer, ... was important in their success. HRA will release top-line findings in a ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only nursing quality ... conference – Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. ... Mason Health System in Seattle since 2000. In addition to his role at Virginia ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing ... sit stand solutions representative to the Minneapolis Home and Garden Show which is being ... that is garnering national attention is the Minneapolis Convention Center. , From its ...
(Date:2/22/2017)... East Setauket, New York (PRWEB) , ... February ... ... the main floor entrance and lobby of a new healthcare contact center in ... gleaming results. , One of the nation’s largest healthcare systems recently invested $51 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 ... report on the global market for intraoperative imaging, ... presently valued at US$ 513.9 million. According to ... keep surging on the grounds of increasing adoption ... the field of diagnostic imaging for neurosurgeries. The ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic Devices ... over the next decade to reach approximately $8.9 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology: